Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    NCT00408005
Show Display Options
Rank Status Study
1 Active, not recruiting Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
Conditions: Adult T Acute Lymphoblastic Leukemia;   Childhood T Acute Lymphoblastic Leukemia;   Stage II Adult T-Cell Leukemia/Lymphoma;   Stage II Childhood Lymphoblastic Lymphoma;   Stage II Contiguous Adult Lymphoblastic Lymphoma;   Stage II Non-Contiguous Adult Lymphoblastic Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Adult T-Cell Leukemia/Lymphoma;   Stage III Childhood Lymphoblastic Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Adult T-Cell Leukemia/Lymphoma;   Stage IV Childhood Lymphoblastic Lymphoma;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
Interventions: Drug: Cytarabine;   Drug: Vincristine Sulfate;   Drug: Daunorubicin Hydrochloride;   Drug: Prednisone;   Drug: Pegaspargase;   Drug: Methotrexate;   Drug: Leucovorin Calcium;   Drug: Cyclophosphamide;   Drug: Mercaptopurine;   Radiation: Radiation Therapy;   Drug: Nelarabine;   Drug: Doxorubicin Hydrochloride;   Drug: Asparaginase;   Drug: Dexamethasone;   Drug: Thioguanine;   Other: Laboratory Biomarker Analysis

Indicates status has not been verified in more than two years